Page last updated: 2024-11-02

pentoxifylline and Bone Loss, Osteoclastic

pentoxifylline has been researched along with Bone Loss, Osteoclastic in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Osteoporosis was measured by in vivo neutron activation analysis and results were confirmed by atomic absorption spectroscopy."1.27Studies on osteoporoses. XI. Effects of a methylxanthine derivative. A preliminary report. ( Ambrus, JL; Robin, JC, 1983)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pal, S1
Porwal, K1
Khanna, K1
Gautam, MK1
Malik, MY1
Rashid, M1
Macleod, RJ1
Wahajuddin, M1
Parameswaran, V1
Bellare, JR1
Chattopadhyay, N1
Robin, JC1
Ambrus, JL1

Other Studies

2 other studies available for pentoxifylline and Bone Loss, Osteoclastic

ArticleYear
Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone.
    Bone, 2019, Volume: 123

    Topics: Administration, Oral; Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cells, Cultu

2019
Studies on osteoporoses. XI. Effects of a methylxanthine derivative. A preliminary report.
    Journal of medicine, 1983, Volume: 14, Issue:2

    Topics: Animals; Bone Resorption; Calcium; Cyclic AMP; Female; Heparin; Mice; Mice, Inbred C3H; Neutron Acti

1983